A study of T-DM1 in combination with docetaxel (with or without trastuzumab) for human HER2-positive breast cancer showed that the combination led to more severe adverse events related to skin toxicity than single-agent T-DM1, and 64% of patients with locally-advanced breast cancer even experienced ≥ grade 3 adverse events [78]. Here, ERBB2 is linked to breast carcinoma.